INTERFERON PRODRUG FOR CANCER TREATMENT Russian patent published in 2023 - IPC A61K38/21 A61K47/65 C07K14/555 C07K14/715 A61P35/00 

FIELD: pharmaceutics.

SUBSTANCE: group of inventions relates to the field of pharmaceuticals and medicine. 1 object is an interferon prodrug for the treatment of cancer containing: (a) interferon alpha and beta receptor 2 domain (IFNAR2), which retains IFN-binding activity; (b) interferon type 1 domain (IFN), which retains the activity of interferon type 1 when it is not bound by the specified IFNAR2 domain; (c) the Fc domain of immunoglobulin (Ig), (d) the first linker fused at one end with the N-end of the specified IFN and fused at the other end with the specified IFNAR2, and the specified first linker is G4S-PVGLIG-G4S; and (e) a second linker fused at one end with the C-end of the specified IFN and fused at the other end with the N-end of the specified Fc-domain Ig. 2-4 objects are a nucleic acid construct encoding an interferon prodrug, a recombinant cell containing a nucleic acid construct, and a method for expressing an interferon prodrug. 5-7 objects suggest the use of the interferon prodrug for the treatment of cancer and in the preparation of a drug, a method for the treatment of cancer, including the administration of the interferon prodrug to the patient.

EFFECT: effectiveness and reduced side effects of an IFN prodrug based on IFNAR2.

26 cl, 7 dwg, 1 tbl, 1 ex